Evidence map›Paper›PMID 42360686›Full record

ArticleMetabolic brain disease2026

Plasma and CSF adiponectin levels in biomarker-confirmed Alzheimer's disease: A cross-sectional study in a tertiary memory clinic.

Louise Sindzingre, Théodore Decaix, Karl Gotze, Paul Baratelli, Marie Bailly, François Mouton-Liger, Emmanuel Cognat, Julien Dumurgier, Agathe Vrillon, Erika Cecon and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Louise SindzingreService de Gériatrie, Université Paris Cité, Institut Pasteur, AP-HP, Hôpital Lariboisière, Fondation Pour l'Audition, IHU reConnect, Paris, F-75010, France. louise.sindzingre@aphp.fr.ORCID 0009-0008-6511-4726
Théodore DecaixService de Gériatrie, Université Paris Cité, Institut Pasteur, AP-HP, Hôpital Lariboisière, Fondation Pour l'Audition, IHU reConnect, Paris, F-75010, France.
Karl GotzeUniversité Paris Cité, Institut Pasteur, Unité INSERM 1144, Fondation Pour l'Audition, IHU reConnect, Paris, F-75010, France.
Paul BaratelliUniversité Paris Cité, Institut Pasteur, Unité INSERM 1144, Fondation Pour l'Audition, IHU reConnect, Paris, F-75010, France.
Marie BaillyUniversité Paris Cité, Institut Pasteur, Unité INSERM 1144, Fondation Pour l'Audition, IHU reConnect, Paris, F-75010, France.
François Mouton-LigerUniversité Paris Cité, Institut Pasteur, Unité INSERM 1144, Fondation Pour l'Audition, IHU reConnect, Paris, F-75010, France.
Emmanuel CognatUniversité Paris Cité, Institut Pasteur, Unité INSERM 1144, Fondation Pour l'Audition, IHU reConnect, Paris, F-75010, France.
Julien DumurgierCentre de Neurologie Cognitive, Université Paris Cité, Institut Pasteur, AP-HP, Hôpital Lariboisière, Fondation Pour l'Audition, IHU reConnect, Paris, F- 75010, France.
Agathe VrillonUniversité Paris Cité, Institut Pasteur, Unité INSERM 1144, Fondation Pour l'Audition, IHU reConnect, Paris, F-75010, France.
Erika CeconUniversité Paris Cité, CNRS, Inserm, Institut Cochin, Paris, F-75014, France.
Claire PaquetUniversité Paris Cité, Institut Pasteur, Unité INSERM 1144, Fondation Pour l'Audition, IHU reConnect, Paris, F-75010, France.
Matthieu Lilamand *Service de Gériatrie, Université Paris Cité, Institut Pasteur, AP-HP, Hôpital Lariboisière, Fondation Pour l'Audition, IHU reConnect, Paris, F-75010, France.
Elodie Bouaziz-Amar *Université Paris Cité, Institut Pasteur, Unité INSERM 1144, Fondation Pour l'Audition, IHU reConnect, Paris, F-75010, France.

Funding

Fondation pour la Recherche Médicale RM11J25CNR01,MND202310017920
6 · The paper itself

Abstract

Adiponectin dysregulation has been implicated in Alzheimer's disease (AD), but the respective roles of total and high-molecular-weight (HMW) adiponectin, as well as central versus peripheral mechanisms, remain unclear. We aimed to investigate the association between biomarker-confirmed AD and plasma total adiponectin, HMW/total adiponectin ratio, and CSF/plasma adiponectin ratio, used as an indirect marker of central-peripheral distribution. We also assessed correlations with CSF amyloid and tau biomarkers. In this monocentric cross-sectional study, 134 participants (90 AD, 44 controls) from a tertiary memory clinic were included. Plasma and CSF total adiponectin were measured by ELISA, and plasma HMW adiponectin by chemiluminescent immunoassay. Associations were analyzed using multivariate linear regression adjusted for age, sex, body mass index, and APOE ε4 carriership. Plasma total and HMW adiponectin levels were higher in AD than in controls (p < 0.05 and p < 0.005, respectively), but the association was no longer significant after adjustment. The HMW/total ratio was higher in AD (0.50 vs. 0.43, p = 0.02), whereas the CSF/plasma ratio did not differ between groups (p = 0.69). No correlations were found between adiponectin (plasma total and HMW, and CSF total) and CSF amyloid or tau biomarkers. Although adiponectin levels were elevated in biomarker-confirmed AD, this association was largely driven by age, sex, and BMI. Overall, adiponectin appears to reflect systemic metabolic and nutritional status rather than AD-specific pathophysiology.

Indexed as

AdiponectinAlzheimer DiseaseAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersCross-Sectional StudiesFemaleHumansMaleMiddle Agedtau ProteinsAdiponectinADIPOQ protein, humanAmyloid beta-PeptidesBiomarkerstau ProteinsAdipokinesAdiponectinAdipose tissueAlzheimer’s diseaseMetabolism

Identifiers

PMID42360686

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.